Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MASS NASDAQ:NAUT NASDAQ:PRE NASDAQ:SEER On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMASS908 Devices$8.10+2.1%$7.31$5.03▼$9.34$299.86M0.63255,782 shs139,106 shsNAUTNautilus Biotechnology$2.33-2.5%$2.84$0.62▼$4.31$303.72M0.75451,204 shs439,275 shsPREPrenetics Global$20.00+0.7%$18.17$6.88▼$23.63$335.12M0.24278,307 shs279,710 shsSEERSeer$1.79$1.83$1.65▼$2.41$98.42M1.6223,862 shs170,996 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMASS908 Devices+2.14%-6.14%-0.86%+29.39%+16.71%NAUTNautilus Biotechnology-2.51%-15.88%-13.06%-4.12%+202.99%PREPrenetics Global+0.70%-1.91%+23.76%+0.30%+140.38%SEERSeer0.00%-4.79%-4.28%+1.13%-21.49%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMASS908 Devices$8.10+2.1%$7.31$5.03▼$9.34$299.86M0.63255,782 shs139,106 shsNAUTNautilus Biotechnology$2.33-2.5%$2.84$0.62▼$4.31$303.72M0.75451,204 shs439,275 shsPREPrenetics Global$20.00+0.7%$18.17$6.88▼$23.63$335.12M0.24278,307 shs279,710 shsSEERSeer$1.79$1.83$1.65▼$2.41$98.42M1.6223,862 shs170,996 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMASS908 Devices+2.14%-6.14%-0.86%+29.39%+16.71%NAUTNautilus Biotechnology-2.51%-15.88%-13.06%-4.12%+202.99%PREPrenetics Global+0.70%-1.91%+23.76%+0.30%+140.38%SEERSeer0.00%-4.79%-4.28%+1.13%-21.49%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMASS908 Devices 2.00Hold$12.0048.15% UpsideNAUTNautilus Biotechnology 2.00Hold$4.0071.67% UpsidePREPrenetics Global 2.50Moderate Buy$32.3361.67% UpsideSEERSeer 3.00Buy$4.00123.46% UpsideCurrent Analyst Ratings BreakdownLatest SEER, NAUT, PRE, and MASS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/11/2026MASS908 Devices Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D-)5/4/2026SEERSeer Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$4.005/4/2026SEERSeer Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$4.004/21/2026NAUTNautilus Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026PREPrenetics Global Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026SEERSeer Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/13/2026MASS908 Devices Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)4/13/2026SEERSeer TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/16/2026PREPrenetics Global Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$29.00(Data available from 6/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMASS908 Devices$56.20M5.45N/AN/A$3.97 per share2.04NAUTNautilus BiotechnologyN/AN/AN/AN/A$1.24 per shareN/APREPrenetics Global$92.39M3.65N/AN/A$9.27 per share2.16SEERSeer$16.58M5.94N/AN/A$4.61 per share0.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMASS908 Devices$19.49M-$1.00N/AN/AN/A-62.40%-14.03%-10.40%8/4/2026 (Estimated)NAUTNautilus Biotechnology-$59M-$0.46N/AN/AN/AN/A-35.04%-29.16%8/4/2026 (Estimated)PREPrenetics Global-$37.71M-$4.02N/AN/AN/A-61.33%-19.61%-15.33%N/ASEERSeer-$73.60M-$1.24N/AN/AN/A-464.78%-26.58%-23.51%8/5/2026 (Estimated)Latest SEER, NAUT, PRE, and MASS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026SEERSeer-$0.2950-$0.30-$0.0050-$0.30$3.60 million$2.79 million4/28/2026Q1 2026NAUTNautilus Biotechnology-$0.1450-$0.12+$0.0250-$0.12$0.25 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthMASS908 DevicesN/AN/AN/AN/AN/ANAUTNautilus BiotechnologyN/AN/AN/AN/AN/APREPrenetics GlobalN/AN/AN/AN/AN/ASEERSeerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMASS908 DevicesN/A3.583.25NAUTNautilus BiotechnologyN/A11.8511.85PREPrenetics GlobalN/A2.972.72SEERSeerN/A17.7316.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMASS908 Devices88.06%NAUTNautilus Biotechnology50.71%PREPrenetics Global25.01%SEERSeer75.20%Insider OwnershipCompanyInsider OwnershipMASS908 Devices28.20%NAUTNautilus Biotechnology41.10%PREPrenetics GlobalN/ASEERSeer11.28%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMASS908 Devices6037.81 million27.15 millionOptionableNAUTNautilus Biotechnology130127.08 million74.85 millionOptionablePREPrenetics Global116.87 millionN/ANot OptionableSEERSeer16054.98 million48.78 millionOptionableSEER, NAUT, PRE, and MASS HeadlinesRecent News About These CompaniesSeer, Inc. Urges Stockholders to Support Board Nominees Amid Proxy Contest with Activist InvestorsJune 3, 2026 | quiverquant.comQSeer Files Definitive Proxy Materials and Mails Letter to StockholdersJune 3, 2026 | globenewswire.comSeer Enters into a Co-Marketing and Sales Agreement with Thermo Fisher ScientificMay 29, 2026 | stockhouse.comSeer Files ITC Complaint Against NanomicsMay 29, 2026 | globenewswire.comThe Radoff-JEC Group Calls on Seer Inc. and Its Advisors to Reevaluate Its Premium Acquisition Proposal in the Best Interests of All StockholdersMay 27, 2026 | businesswire.comSeer to Showcase AI-Driven Multi-Cancer Screening Approach and Next-Generation Proteomics Capabilities at ASMS 2026May 26, 2026 | globenewswire.comInsider Selling: Seer (NASDAQ:SEER) CFO Sells 7,303 Shares of StockMay 22, 2026 | insidertrades.comSeer Board Rejects Revised Radoff-JEC Acquisition ProposalMay 22, 2026 | tipranks.comSeer Board of Directors Unanimously Rejects Further Revised Unsolicited Proposal from Radoff-JEC GroupMay 21, 2026 | globenewswire.comGhana’s first female president?: Prophet Seer 1 issues major prophecy for NDC’s Jomoro MP Dorcas ToffeyMay 19, 2026 | msn.comSeer, Inc. Q1 2026 Earnings Call SummaryMay 15, 2026 | finance.yahoo.comSeer Earnings Call Balances Near-Term Pain, Long-Term PromiseMay 14, 2026 | tipranks.comThe Radoff-JEC Group Submits its Third Non-Binding Proposal to Acquire Seer, Inc.May 14, 2026 | finance.yahoo.comSeer (SEER) Q1 2026 Earnings Call TranscriptMay 14, 2026 | finance.yahoo.comSeer (SEER) price target increased by 33.33% to 4.08May 14, 2026 | msn.comFull Transcript: Seer Q1 2026 Earnings CallMay 14, 2026 | finance.yahoo.comSeer Minority Holders Again Sweeten Offer for CompanyMay 14, 2026 | marketwatch.comSeer Q1 Earnings Call HighlightsMay 13, 2026 | marketbeat.comSeer reaffirms $16M-$18M 2026 revenue guidance amid new patent suit and commercial leadership hireMay 13, 2026 | msn.comSeer, Inc. (SEER) Q1 2026 Earnings Call TranscriptMay 13, 2026 | seekingalpha.comEarnings To Watch: Seer Inc (SEER) Reports Q1 2026 ResultMay 13, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Stocks to Own If Gas Prices Keep RisingBy Dan Schmidt | May 16, 2026Navy Catalyst Ignites Odysight’s Growth EngineBy Jeffrey Neal Johnson | May 12, 2026Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major PlayersBy Nathan Reiff | May 10, 2026Palantir and Dell Build an AI OS for the ParanoidBy Chris Markoch | May 24, 2026Micron’s $1 Trillion Memory Melt-UpBy Jeffrey Neal Johnson | May 27, 2026SEER, NAUT, PRE, and MASS Company Descriptions908 Devices NASDAQ:MASS$8.10 +0.17 (+2.14%) Closing price 06/8/2026 04:00 PM EasternExtended Trading$8.10 0.00 (-0.06%) As of 06/8/2026 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling. Its products also comprise Maven and Trace C2, an online device for bioprocess monitoring and control; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. The company operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of the Americas. 908 Devices Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.Nautilus Biotechnology NASDAQ:NAUT$2.33 -0.06 (-2.51%) Closing price 06/8/2026 04:00 PM EasternExtended Trading$2.40 +0.06 (+2.79%) As of 06/8/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Prenetics Global NASDAQ:PRE$20.00 +0.14 (+0.70%) Closing price 06/8/2026 04:00 PM EasternExtended Trading$20.00 0.00 (0.00%) As of 06/8/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong.Seer NASDAQ:SEER$1.79 0.00 (0.00%) Closing price 06/8/2026 04:00 PM EasternExtended Trading$1.78 -0.01 (-0.28%) As of 06/8/2026 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Technology Stocks Just Got Cheaper—Here Are 5 Mega-Caps Worth a Closer Look Amprius Insiders Are Selling: Should Investors Be Worried? MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? Planet Labs: Coming Back Down to Earth Docusign: Another Beat, Another Selloff—Why the Analysts Are Wrong A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Nebius Is Up Nearly 175% This Year—Here's What's Driving the Latest Run Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
